Physician profile
John C Romano
NPI 1134330558
$2,278.98
in general payments reported to CMS, 2019-2025
25 companies · $533 in 2025
The $533 reported for 2025 was more than what 85% of General Practice providers received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $907 · 2020: $513 · 2021: $223 · 2022: $31.34 · 2024: $71.12 · 2025: $533.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $605.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $604.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $416.47 | 2019-2025 | Trelegy Ellipta |
| Janssen Pharmaceuticals, INC | $218.83 | 2019-2021 | |
| Pfizer INC. | $215.88 | 2019-2025 | |
| Amgen INC. | $123.46 | 2019-2025 | Evenity, Prolia |
| Merck Sharp & Dohme LLC | $122.81 | 2019-2020 | |
| Lilly USA, LLC | $112.68 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $109.50 | 2019-2025 | Jardiance |
| Abbvie INC. | $105.98 | 2020-2025 | |
| Exact Sciences Corporation | $97.61 | 2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Astrazeneca Pharmaceuticals Lp | $96.59 | 2019-2020 | |
| Amarin Pharma, INC. | $94.31 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $85.31 | 2019-2020 | |
| Biohaven Pharmaceuticals, INC. | $73.74 | 2021 | |
| Allergan, INC. | $69.92 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $59.96 | 2025 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $48.04 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $39.03 | 2019 | |
| Novo Nordisk INC | $34.78 | 2025 | Ozempic |
| Sanofi Pasteur INC. | $31.05 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $25.21 | 2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $25.01 | 2025 | Trintellix |
| Esperion Therapeutics, INC. | $24.33 | 2021 | |
| Astellas Pharma US INC | $20.94 | 2019 | |
| Almatica Pharma LLC | $14.89 | 2025 | Loreev Xr |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $12.65 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Romano listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.